The administration does not currently approve the peptide for human use (Technically,no one is allowed to market it for consumer use, though that hasnt stopped people from purchasing research-grade peptides meant only for laboratory use on the gray market)
GLP-1 signaling affects appetite and glucose regulation
TIIDM is primarily found in middle-aged and elderly individuals
Furthermore, it is being investigated for its potential use in chronic weight management, reducing the risk of major adverse cardiovascular events, and managing other conditions such as heart failure with preserved ejection fraction, obesity, and non-cirrhotic non-alcoholic steatohepatitis.The Phase 3 SURPASS 1-5 clinical trial program was conducted to evaluate the safety and effectiveness of tirzepatide, which was administered once weekly through subcutaneous injections at different doses (5, 10, and 15 mg)
doi:10.1007/s00125-014-3263-3 15
2009 Jun